On 7 May 2014 the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct a supplementary assessment for Commission A13-44 (benefit assessment of ipilimumab, new therapeutic indication) and for Commission A14-11 (Addendum to Commission A13-44 [ipilimumab, new therapeutic indication]).
http://ift.tt/2ruYywh
Πέμπτη 15 Ιουνίου 2017
Second Addendum to Commission A13-44 (Ipilimumab, New Therapeutic Indication) [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: September 2017 Source: Free Radical Biology and Medicine, Volume 110 Author(s): Lucía Fernández-del-Río, Anish Nag, Elen...
-
Abstract Noise pollution is a major factor of environmental complaints in many cities, which has significant impacts on human health. As a...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου